Transaction Date | Recipient | Shares | Type | Price | Value |
---|---|---|---|---|---|
19th July 2019 | Dmitry Genkin | 93,390 | Grant/award etc. | $0.00 | |
14th March 2018 | Dmitry Genkin | 29,452 | Other acquisition or disposition | $0.00 |
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.
Xenetic Biosciences, Inc. is a biopharmaceutical company, which focuses on progressing XCART, a personalized CAR T platform technology. The company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient's tumor cells.
20th January 2021
6th November 2020
6th November 2020
6th November 2020